BRPI0914060A2 - formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação - Google Patents

formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação

Info

Publication number
BRPI0914060A2
BRPI0914060A2 BRPI0914060A BRPI0914060A BRPI0914060A2 BR PI0914060 A2 BRPI0914060 A2 BR PI0914060A2 BR PI0914060 A BRPI0914060 A BR PI0914060A BR PI0914060 A BRPI0914060 A BR PI0914060A BR PI0914060 A2 BRPI0914060 A2 BR PI0914060A2
Authority
BR
Brazil
Prior art keywords
formulation
treating cells
hepatitis
carriers
hcv
Prior art date
Application number
BRPI0914060A
Other languages
English (en)
Inventor
Herbert L Bonkovsky
Weihong Hou
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of BRPI0914060A2 publication Critical patent/BRPI0914060A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0914060A 2008-10-08 2009-10-08 formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação BRPI0914060A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10360908P 2008-10-08 2008-10-08
PCT/US2009/059944 WO2010042683A1 (en) 2008-10-08 2009-10-08 Treating hepatitis c virus infection with over-expression of microrna-196

Publications (1)

Publication Number Publication Date
BRPI0914060A2 true BRPI0914060A2 (pt) 2015-11-17

Family

ID=41559924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914060A BRPI0914060A2 (pt) 2008-10-08 2009-10-08 formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação

Country Status (10)

Country Link
EP (1) EP2352829A1 (pt)
JP (1) JP2012505233A (pt)
KR (1) KR20110065568A (pt)
CN (1) CN102257140A (pt)
AR (1) AR073800A1 (pt)
AU (1) AU2009302344A1 (pt)
BR (1) BRPI0914060A2 (pt)
CA (1) CA2739948A1 (pt)
MX (1) MX2011003813A (pt)
WO (1) WO2010042683A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110724734B (zh) * 2019-10-22 2020-06-16 北京恩泽康泰生物科技有限公司 含miRNA mimic的人造脂质体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US8415323B2 (en) * 2007-08-27 2013-04-09 The Regents Of The University Of California MicroRNAs for inhibiting viral replication

Also Published As

Publication number Publication date
AU2009302344A1 (en) 2010-04-15
AR073800A1 (es) 2010-12-01
AU2009302344A2 (en) 2011-04-28
EP2352829A1 (en) 2011-08-10
MX2011003813A (es) 2011-07-28
CA2739948A1 (en) 2010-04-15
CN102257140A (zh) 2011-11-23
JP2012505233A (ja) 2012-03-01
KR20110065568A (ko) 2011-06-15
WO2010042683A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
LTPA2017019I1 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
BRPI0914060A2 (pt) formulação para o tratamento de células que expressem proteínas do hcv e de mamíferos portadores de hepatite c, método para o tratamento de células infectadas pela cepa pj6/jfh1 do hcv genótipo 2a e uso de uma formulação
BR112013022391A2 (pt) composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
CY2015004I1 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE555109T1 (de) Hepatitis-c-virus-hemmer
DK2238142T3 (da) Makrocykliske indoler som hepatitis C-virusinhibitorer
BRPI0907676A2 (pt) Composição, uso de uma composição e método de transferência de calor
AR079504A1 (es) Uso combinado de vip 3ab y cry1fa para el manejo de insectos resistentes
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
EP2501723A4 (en) HEPATITIS B-VIRUS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
IL200432A0 (en) Human antibodies against hepatitis c virus (hcv) uses thereof
DK2050765T3 (da) Fremgangsmåder til anvendelse ved til mennesker tilpassede antistoffer
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
BRPI0913063A2 (pt) Compostos acilaminoácidos e preparações de alimentos que contém os mesmos
CR10571A (es) Vacuna virica recombinante
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
CL2012001321A1 (es) Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
BRPI0819336A2 (pt) meio propulsor e acionamento de corrente
CL2007002758A1 (es) Un procedimiento para la provision de un recipiente cerrado con una atmosfera interna con una concentracion de oxigeno menor que el ambiente, que comprende proporcionar un recipiente permeable al oxigeno, y exponerlo a un material absorbente de oxige
CL2013000670A1 (es) Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv.
BRPI1014516A2 (pt) Biorreator de estado sólido, estático, e método para usar o mesmo
ES1071151Y (es) Dispositivo para el tratamiento de gases, especialmente para el secado de gas natural y biogas
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.